Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (141-150 of 503) with videos related to

Pageof 51
Sort By:
Blood|November 10, 2009
Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AMLBing Z Carter, Duncan H Mak, Wendy D Schober, et al.
Cell Death & Disease|June 23, 2023
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damageRasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, et al.
Leukemia & Lymphoma|August 3, 2002
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disordersApostolia M Tsimberidou, Susan M O'Brien, Jorge E Cortes, et al.
Nature Reviews. Cancer|March 1, 2020
Bone marrow niches in haematological malignanciesSimón Méndez-Ferrer, Dominique Bonnet, David P Steensma, et al.
Apoptosis : an International Journal on Programmed Cell Death|October 13, 2010
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AMLBing Z Carter, Duncan H Mak, Stephen J Morris, et al.
Stem Cells (Dayton, Ohio)|March 3, 2004
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survivalGiuseppe Monaco, Marina Konopleva, Mark Munsell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative StressFuling Zhou, Yunbao Pan, Yongchang Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemiaLouise H Cragg, Michael Andreeff, Eric Feldman, et al.
Journal of Cellular Biochemistry|March 2, 2011
Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cellsPeter P Ruvolo, Liran Zhou, Julie C Watt, et al.
The Journal of Clinical Investigation|December 30, 2009
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis inductionIsmael Samudio, Romain Harmancey, Michael Fiegl, et al.
Pageof 51

Showing results (141-150 of 503) with videos related to

Sort By:
Pageof 51
Blood|November 10, 2009
Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AMLBing Z Carter, Duncan H Mak, Wendy D Schober, et al.
Cell Death & Disease|June 23, 2023
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damageRasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, et al.
Leukemia & Lymphoma|August 3, 2002
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disordersApostolia M Tsimberidou, Susan M O'Brien, Jorge E Cortes, et al.
Nature Reviews. Cancer|March 1, 2020
Bone marrow niches in haematological malignanciesSimón Méndez-Ferrer, Dominique Bonnet, David P Steensma, et al.
Apoptosis : an International Journal on Programmed Cell Death|October 13, 2010
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AMLBing Z Carter, Duncan H Mak, Stephen J Morris, et al.
Stem Cells (Dayton, Ohio)|March 3, 2004
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survivalGiuseppe Monaco, Marina Konopleva, Mark Munsell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative StressFuling Zhou, Yunbao Pan, Yongchang Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemiaLouise H Cragg, Michael Andreeff, Eric Feldman, et al.
Journal of Cellular Biochemistry|March 2, 2011
Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cellsPeter P Ruvolo, Liran Zhou, Julie C Watt, et al.
The Journal of Clinical Investigation|December 30, 2009
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis inductionIsmael Samudio, Romain Harmancey, Michael Fiegl, et al.
Pageof 51